InnoCan Pharma Statistics
Total Valuation
InnoCan Pharma has a market cap or net worth of 37.95 million. The enterprise value is 34.69 million.
| Market Cap | 37.95M |
| Enterprise Value | 34.69M |
Important Dates
The last earnings date was Monday, March 31, 2025.
| Earnings Date | Mar 31, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +8.96% |
| Shares Change (QoQ) | +1.91% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 231.28M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.29 |
| PB Ratio | 5.40 |
| P/TBV Ratio | 7.34 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -18.91 |
| EV / Sales | 1.14 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -21.76 |
Financial Position
The company has a current ratio of 4.09, with a Debt / Equity ratio of 0.00.
| Current Ratio | 4.09 |
| Quick Ratio | 2.48 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.01 |
| Interest Coverage | -178.14 |
Financial Efficiency
Return on equity (ROE) is -4.59% and return on invested capital (ROIC) is -13.61%.
| Return on Equity (ROE) | -4.59% |
| Return on Assets (ROA) | -9.62% |
| Return on Invested Capital (ROIC) | -13.61% |
| Return on Capital Employed (ROCE) | -17.76% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 3.63 |
| Inventory Turnover | 1.28 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -32.72% in the last 52 weeks. The beta is 3.01, so InnoCan Pharma's price volatility has been higher than the market average.
| Beta (5Y) | 3.01 |
| 52-Week Price Change | -32.72% |
| 50-Day Moving Average | 0.13 |
| 200-Day Moving Average | 0.15 |
| Relative Strength Index (RSI) | 81.70 |
| Average Volume (20 Days) | 52 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, InnoCan Pharma had revenue of 29.44 million and -1.83 million in losses. Loss per share was -0.01.
| Revenue | 29.44M |
| Gross Profit | 26.19M |
| Operating Income | -1.25M |
| Pretax Income | 919,000 |
| Net Income | -1.83M |
| EBITDA | -1.21M |
| EBIT | -1.25M |
| Loss Per Share | -0.01 |
Balance Sheet
The company has 5.01 million in cash and 10,000 in debt, giving a net cash position of 5.00 million.
| Cash & Cash Equivalents | 5.01M |
| Total Debt | 10,000 |
| Net Cash | 5.00M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 7.02M |
| Book Value Per Share | 0.02 |
| Working Capital | 6.91M |
Cash Flow
In the last 12 months, operating cash flow was -1.58 million and capital expenditures -15,000, giving a free cash flow of -1.59 million.
| Operating Cash Flow | -1.58M |
| Capital Expenditures | -15,000 |
| Free Cash Flow | -1.59M |
| FCF Per Share | n/a |
Margins
Gross margin is 88.96%, with operating and profit margins of -4.24% and -6.23%.
| Gross Margin | 88.96% |
| Operating Margin | -4.24% |
| Pretax Margin | 3.12% |
| Profit Margin | -6.23% |
| EBITDA Margin | -4.12% |
| EBIT Margin | -4.24% |
| FCF Margin | n/a |
Dividends & Yields
InnoCan Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -8.96% |
| Shareholder Yield | -8.96% |
| Earnings Yield | -4.83% |
| FCF Yield | -4.20% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
InnoCan Pharma has an Altman Z-Score of 12.63.
| Altman Z-Score | 12.63 |
| Piotroski F-Score | n/a |